'Grey's Anatomy' alum Eric Dane prepared to go to extreme measures to fight ALS
Eric Dane is prepared to go to extreme measures to fight ALS.
"I will fly to Germany and eat the head off a rattlesnake if [doctors] told me that that would help," the 52-year-old "Grey's Anatomy" alum told Diane Sawyer during a sit-down interview on "Good Morning America." "I'll assume the risk."
During the interview, which aired Tuesday, Dane opened up about the debilitating disease and explained how he's found hope in the physician who has been leading his care.
"I'm very hopeful... I don't think this is the end of my story," he said. "And whether it is or it isn't, I'm gonna carry that idea with me.
"That's what I got from [Dr. Merit Cudkowicz] when I met her... there was a sense of hope I didn't get from other doctors that I met with," Dane said of his doctor, a neurologist and leading ALS researcher.
Dane said that he had spoken previously with an organization that told him his doctors would be "there to... monitor my decline — and that's not very helpful."
Dr. Cudkowicz said the risk factors behind the disease can include anything from environmental concerns like plastics and bacteria in lakes to sports injuries.
"We worry about head trauma because we do see ALS more common in people in certain sports like football or soccer. We worry about pesticides as well. Being in the military is a risk factor," she said. "Those are the ones we know about, but there's many more we don't know about.
"There's people all over the world working on this," she said, referring to ALS research. "Between artificial intelligence and other imaging technology, that's what gets me excited, and that's all coming in the next, I think, one to two years, if not faster."
Dane, who revealed his diagnosis in April, said in another segment of the interview that aired Monday that he first started experiencing weakness in his right hand before seeking medical attention.
"I didn't really think anything of it at the time," he told Sawyer. "I thought maybe I'd been texting too much and my hand was fatigued. A few weeks later, I noticed it'd gotten a little worse. I went and saw a hand specialist, who sent me to another hand specialist. I went and saw a neurologist, and the neurologist sent me to another neurologist and said, 'This is way above my pay grade.'
"I have one functioning arm," he said. "My left side is functioning. My right side has completely stopped working. [My left arm] is going. I feel like maybe a couple, a few more months, and I won't have my left hand either. It's sobering."
He said that for now, he is able to walk, but added, "I'm worried about my legs."
Dane admitted that he will "never forget" the moment he was diagnosed.
"I will never forget those three letters, [ALS]. It's on me the second I wake up," he said. "It's not a dream."
The actor, who shares two daughters, Billie, 15, and Georgia, 13, with wife Rebecca Gayheart, said he began noticing more of the effects of his disease a few months ago during a boating trip with his daughter.
After jumping into the water, Dane — a former competitive swimmer — quickly realized he was not able to swim.
"[Georgia] dragged me back to the boat," said Dane, who recalled immediately breaking down in tears once on the boat. "I was just, I was, like, heartbroken."
Dane also told Sawyer that he is "angry" about the diagnosis, explaining, "I'm angry because my father was taken from me when I was young, and now there's a very good chance that I'm going to be taken from my girls while they're very young."
"I mean, I really, at the end of the day, just, all I want to do is spend time with my family and work a little bit if I can," he added.
Fox News Digital's Janelle Ash contributed to this post.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SlimJaro Advanced Weight Loss Supplement in 2025: Can Targeting Inflammation Extra Body Fat, Read Slim Jaro Benefits & Side Effects
SlimJaro Supplement Focused Approach to Fat Burn and Weight Management in 2025 Slimjaro New York City, NY, June 20, 2025 (GLOBE NEWSWIRE) --In 2025, weight loss has become more complicated than simply cutting calories or hitting the gym. Many people around the world are following standard health advice yet still struggle with slow or stagnant results. A growing group of health researchers believe the answer may lie deeper — in inflammation. At the center of this shift is SlimJaro, a new inflammation-focused supplement that aims to help the body naturally release stored fat by targeting internal blockages rather than relying on extreme diets or stimulants. While traditional 'eat less, move more' advice still holds merit, new insights suggest that the body's ability to burn fat is not just about math — it's also about biology. Inflamed fat cells, hormone imbalances, chronic stress, and poor digestion may all play a role in keeping fat 'locked' in place, even when lifestyle changes are made. Why Weight Loss in 2025 Is Harder Than Ever Despite more awareness around healthy eating and exercise, obesity rates remain high across all age groups. Part of the reason is that weight loss has historically focused on symptoms (like appetite or cravings) rather than causes. But new science is revealing some hidden factors:Chronic Inflammation: When fat cells become inflamed — often due to stress, poor diet, environmental toxins, or metabolic syndrome — they can become 'resistant' to fat-burning signals. Cortisol and Insulin Spikes: High stress raises cortisol, which encourages fat storage, especially around the belly. Meanwhile, insulin spikes from processed food can prevent fat breakdown. Poor Digestion and Gut Health: An unbalanced gut microbiome, frequent bloating, or sluggish digestion may impair nutrient absorption and keep metabolism slow. Sleep and Hormones: Lack of sleep and irregular routines disrupt hormonal rhythms that govern hunger and fat storage. This complexity has led many to explore new types of support tools — not to replace diet and exercise, but to work with the body's deeper processes. What Is SlimJaro? According to the official product website (https::// SlimJaro is a U.S.- made, non-GMO dietary supplement designed to support weight management by calming inflammation in the body, particularly in fat tissue. Unlike fat burners loaded with caffeine or synthetic ingredients, SlimJaro relies on plant-based extracts that support metabolism, digestion, and hormone than acting as a quick fix, it aims to act gently over time — restoring balance to systems that are often overlooked in conventional weight loss Makes SlimJaro Different? SlimJaro's approach is unique for a few reasons:Targets Inflammation in Fat Cells: Uses anti-inflammatory compounds like Boswellia, MSM, and Reishi Mushroom to calm fat tissue and support fat release. Mild Thermogenic Effect: Ingredients like Ginger Root gently boost metabolic rate without causing anxiety or heart racing. Digestive Support: Aloe Vera and other plant compounds support gut function, helping reduce bloating and promote regularity. • Stress & Hormonal Balance: Adaptogens like Reishi Mushroom may help regulate cortisol levels, which are often elevated in those who experience stubborn ingredient was selected based on its potential to work with the body rather than against it — aiming to reduce the biological resistance many people face when trying to lose Ingredients and Their Functions Ingredient Primary Role MSM (Methylsulfonylmethane) Anti-inflammatory, supports detox and cell health. Helps release fat stored in inflamed cells. Ginger Root Powder Boosts mild thermogenesis, helps regulate appetite and digestion. Boswellia Serrata Reduces systemic inflammation and supports gut and joint health. Ganoderma Lucidum (Reishi) Modulates stress hormones like cortisol, improves immune balance. Aloe Vera Extract Supports digestion, eases bloating, promotes a healthy gut lining. Arnica Montana Enhances circulation, may support nutrient delivery and tissue recovery. Magnesium (from Epsom Salt) Supports nerve and muscle function, sleep, and blood sugar control. This formulation is manufactured in a GMP-certified and FDA-registered facility in the U.S., with third-party testing to ensure quality and safety. What the Science Suggests Emerging research supports the connection between inflammation and obesity. A 2024 review published in Frontiers in Endocrinology noted that 'chronic low-grade inflammation in adipose tissue plays a key role in obesity-related metabolic dysfunction.' When fat cells are inflamed, they hold onto stored lipids, making it harder to lose weight even with caloric claims to address this root cause. While more peer-reviewed studies are needed on the specific formulation, the individual ingredients have shown promise in early Real Users Are Saying Early adopters of SlimJaro report a mix of outcomes:Many users say they noticed less bloating, steadier appetite, and improved energy within the first 2–3 weeks. A few report modest fat loss, especially around the midsection, without changing their diet significantly. Others did not experience noticeable changes and suggest it works better when paired with healthy SlimJaro has earned attention for its lack of stimulant side effects — no racing heart, nausea, or insomnia, which are common with traditional fat Might Benefit from SlimJaro? SlimJaro Supplement may be worth exploring for individuals who:Struggle with weight loss despite eating healthy and exercising Have signs of chronic inflammation (joint pain, bloating, fatigue) Experience stress-related eating or cortisol imbalance Prefer a gentle, stimulant-free supplement that supports long-term healthOf course, it's always recommended to consult with a healthcare provider before starting any new supplement. Visit SlimJaro Official Website To Read More.. Final Thoughts on Slim Jaro Supplement: A New Path in Weight Management? While SlimJaro is not a miracle pill, its inflammation-centered approach represents a promising shift in how we think about body weight, metabolism, and wellness in 2025. As research continues to uncover the connections between inflammation, gut health, hormones, and fat storage, supplements like SlimJaro may serve as part of a more personalized and effective path to long-term weight and Contact InformationContact: Slimjaro Website: https::// Address: PO Box 90129, Lakeland, FL 33804, USA Phone: +1.833.746.6887 or +1.833.746.5587 Email: support@ -------- Contact Us for Advertising: rajneesh08verma@ Attachment Slimjaro CONTACT: Contact: Slimjaro Website: https::// Address: PO Box 90129, Lakeland, FL 33804, USA Phone: +1.833.746.6887 or +1.833.746.5587 Email: support@
Yahoo
an hour ago
- Yahoo
The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/ -- Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity 2025 Updates symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. The Obesity Association™, a division of the ADA, recently announced the publication of Weight Stigma and Bias: Standards of Care in Overweight and Obesity—2025, along with the Introduction & Methodology section in BMJ Open Diabetes Research & Care. This comes at a time when about 110 million American adults are impacted by obesity. Further, up to (53%) of new cases of type 2 diabetes are attributed to obesity every year, demonstrating the need for comprehensive, evidence-based guidelines to inform care. The symposium highlighted key insights on physician guidelines for weight stigma and bias, including training for health care professionals, creating inclusive clinical environments, person-centered communication, shared decision making, and evidence-based interventions. Additionally, researchers highlighted what is next for the clinical guidelines, including a potential section for pharmacologic treatment and a preview of what is going to be covered in that section. The Standards of Care in Overweight and Obesity 2025 Updates symposium is one of many obesity-related symposia and abstracts at the 85th Scientific Sessions, spanning basic through clinical and implementation science. Additional studies highlighting groundbreaking developments obesity treatment and care to be presented at ADA's annual meeting include: Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes—A 52-Week Phase 2 Study ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) Trial Outcomes Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide PATHWEIGH Trial—Building the Highway for Weight Management in Primary Care First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control—The ACHIEVE-1 Trial Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials "The ADA's Standards of Care in Diabetes guideline is the gold standard for diabetes care and management," said Raveendhara Bannuru, MD, PhD, the ADA's vice president, medical affairs and lead author of the guidelines. "The new Standards of Care in Overweight and Obesity guidelines stand to yield significant impact and progress in patient care, and it's only just the beginning." As part of the ADA's ongoing commitment to combating obesity, new clinical practice guidelines and initiatives are continually being developed to advance the quality of care. Research presentation details:Dr. Bannuru and other Professional Practice Committee members will present these findings at the symposium: Standards of Care in Overweight and Obesity 2025 Updates Friday, June 20 from 12:45–1:45 p.m. About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the Obesity Association Obesity is an epidemic that demands both attention and action. The Obesity Association, a division of the American Diabetes Association, is dedicated to reducing the prevalence of obesity and improving health outcomes. Through a focus on education, action, and evidence-based support, we strive to create a world where people affected by obesity can thrive. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio
